Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lessons for clinical trials from natalizumab in multiple sclerosis.

× No keyword cloud information.

17 in total

1. Natalizumab for relapsing multiple sclerosis.

Authors: Abhijit Chaudhuri; Peter O Behan
Journal: N Engl J Med Date: 2003-04-17 Impact factor: 91.245

2. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

Authors: Maja Eriksson; Oluf Andersen; Björn Runmarker
Journal: Mult Scler Date: 2003-06 Impact factor: 6.312

3. Interferon beta, progressive MS, and brain atrophy.

Authors: Abhijit Chaudhuri
Journal: Lancet Neurol Date: 2005-04 Impact factor: 44.182

Review 4. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

Authors: George P A Rice; Hans-Peter Hartung; Peter A Calabresi
Journal: Neurology Date: 2005-04-26 Impact factor: 9.910

5. Is the FDA approving drugs too fast?. Probably not--but drug recalls have sparked debate.

Authors: J D Kleinke; S Gottlieb
Journal: BMJ Date: 1998-10-03

6. Long-term treatment with anti-alpha 4 integrin antibodies aggravates colitis in G alpha i2-deficient mice.

Authors: Malin Bjursten; Paul W Bland; Roger Willén; Elisabeth Hultgren Hörnquist
Journal: Eur J Immunol Date: 2005-08 Impact factor: 5.532

7. Treatment of multiple sclerosis: beyond the NICE guidelines.

Authors: A Chaudhuri; P O Behan
Journal: QJM Date: 2005-04-08

8. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

Authors: P W O'Connor; A Goodman; A J Willmer-Hulme; M A Libonati; L Metz; R S Murray; W A Sheremata; T L Vollmer; L A Stone
Journal: Neurology Date: 2004-06-08 Impact factor: 9.910

9. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

Authors: N Tubridy; P O Behan; R Capildeo; A Chaudhuri; R Forbes; C P Hawkins; R A Hughes; J Palace; B Sharrack; R Swingler; C Young; I F Moseley; D G MacManus; S Donoghue; D H Miller
Journal: Neurology Date: 1999-08-11 Impact factor: 9.910

10. A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors: David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal: N Engl J Med Date: 2003-01-02 Impact factor: 91.245

2 in total

Review 1. Monitoring medicines use: the role of the clinical pharmacologist.

Authors: David Williams
Journal: Br J Clin Pharmacol Date: 2012-10 Impact factor: 4.335

2. The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis.

Authors: Qing Li; Kristine Nacion; Hong Bu; Feng Lin
Journal: Am J Pathol Date: 2009-07-16 Impact factor: 4.307

2 in total